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Background: In contrast to the well-described epidemiology and behavior of small cell lung carcinoma (SCLC), little
is known about extrapulmonary small cell carcinoma (EPSCC).
Methods: Using data from the Surveillance, Epidemiology and End Results (SEER) Program (1992–2010), we
calculated age-adjusted incidence rates (IRs), IR ratios (IRRs), annual percent change (APC), relative survival (RS), RS
ratios (RSRs), and the respective 95% confidence intervals (95% CI) of SCLC and EPSCC according to primary site.
We used the SEER historic stage variable that includes localized (confined to the organ of origin), regional (direct
extension to adjacent organ/tissue or regional lymph nodes), and distant (discontinuous metastases) stages and
combined localized and regional stages into “limited” stage.
Results: The incidence of SCLC (IR = 76.3/million person-years; n = 51,959) was 22-times that of EPSCC (IR = 3.5;
n = 2,438). Of the EPSCC sites, urinary bladder, prostate, and uterine cervix had the highest incidence (IRs = 0.7-0.8);
urinary bladder (IRR = 4.91) and stomach (IRR = 3.46) had the greatest male/female disparities. Distant-to-limited
stage site-specific IRRs of EPSCC were significantly elevated for pancreas (IRR = 6.87; P < 0.05), stomach, colon/
rectum, ovary, and prostate (IRRs = 1.62-2.42; P < 0.05) and significantly decreased for salivary glands, female breast,
uterine cervix, and urinary bladder (IRRs = 0.32-0.46). During 1992–2010, significant changes in IRs were observed for
EPSCC overall (APC = 1.58), small cell carcinoma of the urinary bladder (APC = 6.75), SCLC (APC = −2.74) and small
cell carcinoma of unknown primary site (APC = −4.34). Three-year RS was significantly more favorable for patients
with EPSCC than SCLC for both limited (RSR = 2.06; 95% CI 1.88, 2.26) and distant stages (RSR = 1.55; 95% CI 1.16,
2.07). Among limited stage small cell carcinoma, RS was most favorable for salivary glands, female breast, and
uterine cervix (RS = 52-68%), whereas RS for nearly all sites with distant stage disease was <10%.
Conclusion: EPSCC comprises a heterogeneous group of diseases that appears, at least in part, etiologically distinct
from SCLC and is associated with more favorable stage-specific patient survival.
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In the broad spectrum of neuroendocrine tumors, small
cell carcinomas comprise the less differentiated tumors
associated with aggressive behavior [1]. Most of what is
known regarding the epidemiology of small cell carcin-
oma is derived from studies of lung cancer. Indeed, of
the major lung cancer types, cigarette smoking has been
most strongly associated with small cell lung carcinoma
(SCLC) [2,3]. Risk factors for extrapulmonary small cell
carcinoma (EPSCC) are unknown. While population-based
epidemiologic studies of neuroendocrine tumors have con-
sidered incidence according to anatomic site, most have
excluded small cell histology, based on the assumption that
these aggressive, highly fatal tumors are etiologically dis-
tinct from their well-differentiated counterparts [4-7]. Few
studies of EPSCC have assessed incidence and patient sur-
vival by site [8,9], and although some studies have focused
on selected sites [10-12], to our knowledge, none have
been comprehensive in their inclusion of topography
while describing site-specific incidence rates and pa-
tient survival. To gain insight into the etiology and
behavior of small cell carcinoma, we comprehensively
assessed SCLC and EPSCC incidence and patient sur-
vival using population-based data from the National
Cancer Institute’s Surveillance, Epidemiology and End
Results (SEER) Program.
Methods
We assessed incidence of small cell carcinoma based on
cases diagnosed among residents of 13 cancer registry
areas of the SEER (SEER-13) Program during 1992–2010.
SEER-13 represents approximately 14% of the population
of the U.S. and includes the states of Connecticut,
Hawaii, Iowa, New Mexico, and Utah and the areas of
Detroit, Michigan; San Francisco, Los Angeles, and
San Jose-Monterey, California; Seattle-Puget Sound,
Washington; Atlanta and rural Georgia; and the Alaska
Native Tumor Registry. The SEER Program classifies
histology and topography information according to the
International Classification of Diseases for Oncology
(ICD-O), and all cases have been recoded to the third
edition of ICD-O (ICD-O-3) by the SEER Program [13].
Using SEER*Stat, version 8.1.2 (www.seer.cancer.gov),
we calculated incidence rates (IRs), IR ratios (IRRs), and
corresponding 95% confidence intervals (CIs) for all
cases of microscopically confirmed small cell carcinoma
(ICD-O-3 morphology codes 8041–8045) with malignant
behavior (ICD-O-3 behavior code/3) according to pri-
mary site (topography codes specified in Table 1). Over-
all, 834 cases (1.5% of total) were not microscopically
confirmed and were excluded from the study. Malignant
tumor, small cell type (8002) was excluded due to being a
nonspecific code and potentially including other malignan-
cies characterized by small cells (e.g., malignant melanoma,lymphoma) [14]. All IRs were age-adjusted to the 2000
U.S. standard population and expressed per one million
person-years (PY). IRs were assessed according to gender,
age, calendar year, and stage. To allow a general overview
of stage across primary sites, we used the SEER historic
stage variable that includes localized (confined to the organ
of origin), regional (direct extension to adjacent organ/tis-
sue or regional lymph nodes), distant (discontinuous me-
tastases), and unspecified stages. We combined localized
and regional stages into the category of “limited” stage and
maintained the distant stage variable as defined in SEER.
Our “limited” and “distant” stage categories are intended to
approximate the two-tier SCLC staging systems of the
Veterans Administration Lung Study Group and the Inter-
national Association for the Study of Lung Cancer [15].
Age-specific IRs (<15, 15–24, 25–34, 35–44, 45–54,
55–64, 65–74, 75+ years) were calculated and depicted
on a log-linear scale as previously described [16]. Annual
percent change (APC) in incidence was calculated using
the weighted least squares method. We used the Join-
point Regression Program (version 4.1.1.3) to assess the
best fit for trend data and allowed up to 3 Joinpoints
(http://surveillance.cancer.gov/joinpoint). Following the
SEER Program convention, IRs are not presented for
fewer than 16 cases [17].
Relative survival (RS) for cases diagnosed during 1992–
2010 and followed through 2011 was estimated using the
actuarial method in the SEER*Stat Survival Session. RS is
the ratio of the proportion of observed survivors in a co-
hort of patients to the proportion of expected survivors in
a comparable cohort of the general population [18]. We
estimated 3-year RS, RS ratios (RSRs), and 95% CIs over-
all, according to site, stage, gender, age, primary tumor
size, and calendar year. To allow comparison with previ-
ously published studies describing 5-year survival, we cal-
culated 5-year RS for SCLC and EPSCC (Additional file 1:
Table S1 and Additional file 2: Table S2). We excluded in-
dividuals with second or later primary cancers (n = 9,848),
cases diagnosed by death certificate or autopsy (n = 134),
those with unknown age (n = 4), and those alive with un-
known survival time (n = 6). In total, 45,747 cases were
available for the survival analysis. Following SEER conven-
tion, RS rates based on fewer than 25 cases are not pre-
sented [17].
Results
Overall, 55,722 cases of small cell carcinoma were diag-
nosed among residents of SEER-13 during 1992–2010
(IR = 81.8/million PY). The incidence of SCLC (n = 51,959;
IR = 76.3) was 22 times that of EPSCC (n = 2,438; IR = 3.5),
accounting for 93% of cases of small cell carcinoma. Of the
extrapulmonary sites, IRs were highest for urinary bladder,
prostate, and uterine cervix (Table 1). Small cell carcinoma
IR was 35% higher among men than women, with the
Table 1 Age-adjusted incidence rates and incidence rate ratios of small cell lung carcinoma and extrapulmonary small
cell carcinoma according to primary site and gender, SEER-13, 1992-2010*
ICD-O-3 Males Females Male-to-female
Site topography codes No. IR No. IR IRR (95 % CI)
Total§ 00.0-80.9 28,820 96.20 26,902 71.44 1.35 (1.32, 1.37)†
SCLC 34.0-34.9 26,798 89.19 25,161 66.88 1.33 (1.31, 1.36)†
EPSCC 00.0-33.9, 35.0-75.9, 77.0-77.9 1,272 4.41 1,166 3.06 1.44 (1.33, 1.56)†
Salivary glands 07.9-08.9 44 0.16 <16 ~ ~
Esophagus 15.0-15.9 106 0.36 81 0.21 1.72 (1.27, 2.33)†
Stomach 16.0-16.9 64 0.21 24 0.06 3.46 (2.12, 5.80)†
Colon/rectum 18.0-20.9 125 0.42 113 0.30 1.41 (1.08,1.84)†
Anus 21.0-21.8 16 0.05 21 0.06 0.95 (0.46, 1.91)
Liver/intrahepatic bile ducts 22.0-22.1 18 0.06 <16 ~ ~
Gallbladder 23.9 <16 ~ 30 0.08 ~
Pancreas 25.0-25.9 89 0.30 84 0.22 1.38 (1.01, 1.88)†
Nose, nasal cavity, middle ear 30.0-30.1, 31.0-31.9 21 0.07 16 0.04 1.56 (0.77, 3.21)
Larynx 32.0-32.9 37 0.11 27 0.07 1.57 (0.93, 2.68)
Breast 50.0-50.9 <16 ~ 68 0.18 ~
Vagina 52.9 NA NA 37 0.10 ~
Cervix 53.0-53.9 NA NA 260 0.69 ~
Uterus 54.0-55.9 NA NA 56 0.15 ~
Ovary 56.9 NA NA 111 0.29 ~
Prostate 61.9 206 0.73 NA NA ~
Kidney and renal pelvis 64.9, 65.9 22 0.07 <16 ~ ~
Urinary bladder 67.0-67.9 411 1.48 118 0.30 4.91 (3.99, 6.09)†
Unknown primary 76.0-76.8, 80.9 750 2.61 575 1.50 1.73 (1.55, 1.94)†
Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, ICD-O-3 third edition of the International Classification of Diseases for Oncology,
NA not applicable, No. number of cases, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results
Program, ~ IRs and IRRs are not calculated for <16 cases.
*Incidence rates are age-adjusted to the 2000 U.S. standard population and expressed per 1,000,000 person-years. IRRs are based on unrounded rates.
†95 % CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P < 0.05).
§Specified sites with 1–15 total cases not shown in the table (ICD-O-3 code): tongue (01.1-0.29), gum and other mouth (03.0-03.9, 05.0-05.9, 06.0-06.9), tonsil
(09.0-09.9), oropharynx (10.0-10.9), hypopharynx (12.9, 13.0-13.9), other oral cavity and pharynx (14.0-14.8), small intestine (17.0-17.9), intestinal tract, unspecified
(26.0-26.9), soft tissues, including heart (38.0, 47.0-47.9 49.0-49.9), retroperitoneum/peritoneum (48.0-48.8), vulva (51.0-51.9), other female genital (57.0-58.9), testis
(62.0-62.9), other male genital (63.0-63.9), ureter (66.9), eye and orbit (69.0-69.9), thyroid (73.9), other endocrine (37.9, 74.0-74.9, 75.0-75.9), and lymph nodes
(77.0-77.9). Sites with >15 cases, but with fewer than 16 among both, males and females, not specified in the table (No., IR, ICD-O-3 code): nasopharynx (No. = 23;
IR = 0.03; 11.0-11.9), other biliary (No. = 19; IR = 0.03; 24.0-24.9), and trachea/mediastinum/other respiratory (No. = 25; IR = 0.04; 33.9, 38.1-39.9).
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and stomach (male-to-female (M/F) IRR = 4.91 and
3.46, respectively).
IRs of SCLC and EPSCC increased exponentially with
advancing age among men and women, most rapidly for
SCLC among both men and women and least rapidly for
EPSCC among women (Figure 1). Significant gender dif-
ferences in SCLC IRs were apparent beginning at ages
45–54 years (M/F IRR = 1.14; 95% CI 1.07, 1.20), peaking
at the oldest age group (≥75 years; M/F IRR = 1.60; 95%
CI 1.55, 1.65). In contrast, the M/F IRRs for EPSCC rose
from a female excess through ages 45–54 years (M/F
IRR = 0.77; 95% CI 0.60, 0.97) to a male excess starting
at ages 55–64 years (M/F IRR = 1.38; 95% CI 1.14, 1.67)and increasing progressively until ≥75 years (IRR = 2.47;
95% CI 2.14, 2.85). Among EPSCC diagnosed prior to
age 55 years, uterine cervix (n = 156) and ovary (n = 75)
comprised 61% of 379 cases among women, whereas
the urinary bladder (n = 37) and colon/rectum (n = 33)
accounted for the largest proportion (39%) of the 179
cases among men.
In contrast to SCLC where incidence of distant stage dis-
ease predominated over limited stage (distant/limited IRR
= 2.32, 95% CI 2.28, 2.37), incidence of limited stage
EPSCC was significantly higher than distant stage (distant/
limited IRR = 0.89, 95% CI 0.82, 0.97) (Table 2). The dis-
tant/limited stage IRR was significantly elevated for small
cell carcinoma of the stomach, colon/rectum, pancreas,
Figure 1 Age-specific incidence rates of small cell lung carcinoma and extrapulmonary small cell carcinoma diagnosed in 13 cancer
registry areas of the Surveillance, Epidemiology and End Results Program during 1992–2010 according to gender.
Table 2 Age-adjusted incidence rates and incidence rate ratios of small cell lung carcinoma and extrapulmonary small
cell carcinoma according to primary site and stage, SEER-13, 1992-2010*
Limited Distant Not specified Distant-to-limited
Site No. IR No. IR No. IR IRR (95% CI)
Total 16,142 23.69 35,813 52.51 3,767 5.57 2.22 (2.18, 2.26)†
SCLC 14,963 21.98 34,770 50.99 2,226 3.30 2.32 (2.28, 2.37)†
EPSCC 1,179 1.71 1,043 1.52 216 0.31 0.89 (0.82, 0.97)†
Salivary glands 37 0.06 16 0.02 <16 ~ 0.44 (0.23, 0.81)†
Esophagus 73 0.11 93 0.14 21 0.03 1.27 (0.92, 1.75)
Stomach 22 0.03 53 0.08 <16 ~ 2.42 (1.45, 4.17)†
Colon/rectum 76 0.11 152 0.22 <16 ~ 1.95 (1.47, 2.61)†
Gallbladder 16 0.02 24 0.04 <16 ~ 1.48 (0.75, 2.97)
Pancreas 20 0.03 140 0.21 <16 ~ 6.87 (4.30, 11.61)†
Breast (female) 47 0.12 21 0.05 <16 ~ 0.44 (0.25, 0.75)†
Cervix 174 0.46 80 0.21 <16 ~ 0.46 (0.35, 0.60)†
Uterus 28 0.07 25 0.07 <16 ~ 0.91 (0.51, 1.62)
Ovary 35 0.09 72 0.19 <16 ~ 2.11 (1.38, 3.25)†
Prostate 66 0.23 108 0.38 32 0.11 1.62 (1.18, 2.25)†
Urinary bladder 390 0.58 123 0.18 16 0.02 0.32 (0.26, 0.39)†
Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, No. number of cases, SCLC small cell lung carcinoma, SEER-13 13 cancer registry
areas of the Surveillance, Epidemiology and End Results (SEER) Program, ~ IRs are not calculated for <16 cases.
*Incidence rates are age-adjusted to the 2000 U.S. standard population and expressed per 1,000,000 person-years. IRRs are based on unrounded rates. To allow a
general overview of stage across primary sites, we used the SEER historic stage variable that includes localized (confined to the organ of origin), regional (direct
extension to adjacent organ/tissue or regional lymph nodes), distant (discontinuous metastases), and unspecified stages. We combined localized and regional
stages into the category of “limited” stage and maintained the distant stage variable as defined in the SEER Program.
†95 % CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P < 0.05).
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creased for salivary glands, female breast, uterine cervix,
and urinary bladder.
Whereas the incidence of SCLC decreased during 1992–
2010 (APC = −2.74; P < 0.05), the incidence of EPSCC in-
creased significantly (APC= 1.58; P < 0.05), largely related
to the marked rise in small cell carcinoma of the urinary
bladder (APC = 6.75; P < 0.05) (Figure 2). Similar to SCLC,
only the incidence of small cell carcinoma of unknown
primary site decreased over this timeframe (APC= −4.34;
P < 0.05). APC did not change significantly for any other
site for which APC could be calculated. All trend data were
best fitted with 0 joinpoints.
Among patients with limited stage disease, 3-year RS was
significantly more favorable for patients with EPSCC than
SCLC overall, among males and females <60 and ≥60 years,
whites <60 years, whites and blacks ≥60 years, accord-
ing to tumor size, and by calendar year period (Table 3).
Among patients with distant stage small cell carcinoma,
RS was poor but signifcantly better for EPSCC than for
SCLC overall, among white males <60 years of age, for
tumor size >7 cm, and for cases diagnosed 2001–2010.
Compared to 1992–2000, survival during 2001–2010 in-
creased significantly for limited (limited/distant RSR =
1.22, 95% CI 1.13, 1.31) and distant stage (limited/distant
RSR = 1.26, 95% CI 1.09, 1.45) SCLC but not for limited
(limited/distant RSR = 1.07, 95% CI 0.90, 1.27) or distant
stage (limited/distant RSR = 1.22, 95% CI 0.68, 2.18)
EPSCC. To allow comparison of RS by EPSCC sites, we
used uterine cervix as the referent site, since there were
sufficient cases to allow stable comparisons for both, lim-
ited and distant stage disease (Table 4). Compared to
small cell carcinoma of the uterine cervix, 3-year RS was
significantly less favorable for limited stage small cellFigure 2 Annual percent change of small cell lung carcinoma
and extrapulmonary small cell carcinoma diagnosed in 13
cancer registry areas of the Surveillance, Epidemiology and End
Results Program during 1992–2010 according to site.carcinoma of the esophagus (RSR = 0.64, 95% CI 0.42,
0.98) and urinary bladder (RSR = 0.78, 95% CI 0.62, 0.99),
whereas for distant stage disease, pancreas was associated
with significantly less favorable survival (RSR = 0.19, 95%
CI 0.04, 0.96).Discussion
This is among the first population-based studies to de-
scribe distinct differences in incidence patterns between
SCLC and EPSCC, suggesting etiologic differences, with
the most convincing evidence arising from opposing
temporal trends across sites. With the decrease in SCLC
attributed to declining cigarette smoking, our findings
raise the possibility that tobacco may have a less import-
ant role in the etiology of EPSCC overall, and also in
small cell carcinoma of the bladder. Etiologic heterogen-
eity is also suggested by site-specific differences in inci-
dence of EPSCC by gender, possibly reflecting varying
environmental exposures and/or inherent susceptibility.
Differences in stage at presentation of site-specific EPSCC
may be due to distinct disease biology, since sites for
which screening is available did not all present with less
advanced disease (e.g., prostate), although diagnostic chal-
lenges could also affect stage at presentation. RS differ-
ences by site also suggest distinct biologic behavior and/or
responsiveness to therapy.
Our findings differ from a 1970–2004 population-
based study of 1,618 cases of EPSCC from South East
England where EPSCC predominated among women
(male:female case ratio of 1:1.3, comparable to a case ra-
tio of 0.77) [9], in contrast to our case ratio of 1.09. In
South East England, small cell carcinoma of the esopha-
gus comprised the majority of EPSCC (18%), followed by
stomach (6%) and prostate (6%). Among our 2,438 cases
of EPSCC, the largest fractions were of the urinary blad-
der (22%), uterine cervix (11%), and colon/rectum (10%).
While these findings may reflect differences in study de-
sign, calendar years of study, histologic entities included,
or population characteristics, they also support potential
differences in exposures or susceptibility between indi-
viduals in the U.S. and South East England. A literature
review including more than 130 reports of gastrointes-
tinal small cell carcinoma during 1970–2003 also identi-
fied esophagus as the most commonly reported primary
site, accounting for 53% (n = 290/544 cases) of gastro-
intestinal small cell carcinomas [19]. While tobacco and
alcohol use were found to be prevalent among patients
in these series, an association with these or other puta-
tive risk factors has not been identified [19,20]. The dif-
ferences in frequency of site-specific EPSCC across
studies may reflect various factors, including time periods
of study, accuracy of cancer reporting to cancer registries,
varying extent of screening, distinct exposures among
Table 3 Stage-specific three-year relative survival of patients with small cell lung carcinoma and extrapulmonary small
cell carcinoma diagnosed in SEER-13 according to gender, age, and calendar year, 1992-2010*
SCLC EPSCC EPSCC-to-SCLC
Stage No. RS (%) (95% CI) No. RS (%) (95% CI) RSR (95% CI)
Total†
Limited 12,070 20.7 (19.9, 21.5) 907 42.7 (39.1, 46.2) 2.06 (1.88, 2.26)‡
Distant 29,003 4.0 (3.7, 4.2) 835 6.2 (4.6, 8.1) 1.55 (1.16, 2.07)‡
Gender and age
Males, <60 years
Limited 1,407 24.9 (22.6, 27.3) 124 37.0 (28.2, 45.7) 1.49 (1.15, 1.92)‡
Distant 3,993 4.8 (4.2, 5.5) 121 7.8 (3.8, 13.6) 1.63 (0.85, 3.11)
Females, <60 years
Limited 1,442 31.2 (28.7, 33.7) 251 51.8 (45.2, 58.1) 1.66 (1.43, 1.93)‡
Distant 3,043 7.2 (6.2, 8.1) 169 11.1 (6.7, 16.8) 1.54 (0.96, 2.49)
Males, ≥60 years
Limited 4,469 16.8 (15.6, 18.0) 312 40.3 (34.0, 46.6) 2.40 (2.02, 2.85)‡
Distant 11,594 2.8 (2.5, 3.1) 297 3.7 (1.8, 6.7) 1.32 (0.69, 2.53)
Females, ≥60 years
Limited 4,752 19.7 (18.5, 21.0) 220 38.8 (31.6, 45.9) 1.97 (1.62, 2.40)‡
Distant 10,373 4.0 (3.6, 4.4) 248 4.9 (2.6, 8.4) 1.23 (0.67, 2.25)
Race and age
Whites, <60 years
Limited 2,360 28.9 (27.1, 30.8) 282 47.0 (40.8, 52.9) 1.63 (1.41, 1.88)‡
Distant 5,849 5.7 (5.1, 6.4) 224 10.1 (6.5, 14.7) 1.77 (1.16, 2.70)‡
Blacks, <60 years
Limited 327 21.3 (16.9, 26.1) 44 25.1 (13.3, 38.9) 1.18 (0.67, 2.08)
Distant 796 5.1 (3.7, 6.9) 36 10.7 (3.2, 23.5) 2.10 (0.76, 5.81)
Whites, ≥60 years
Limited 7,887 18.5 (17.6, 19.4) 449 38.7 (33.4, 43.8) 2.09 (1.81, 2.42)‡
Distant 18,793 3.3 (3.0, 3.6) 451 4.5 (2.7, 7.0) 1.36 (0.84, 2.21)
Blacks, ≥60 years
Limited 699 16.5 (13.6, 19.6) 41 47.5 (30.6, 62.6) 2.88 (1.95, 4.25)‡
Distant 1,770 3.2 (2.4, 4.2) 50 4.3 (0.8, 13.1) 1.34 (0.33, 5.46)
Primary tumor size
≤3 cm
Limited 2,930 29.2 (27.5, 31.0) 187 57.1 (48.8, 64.6) 1.96 (1.68, 2.27)‡
Distant 4,469 5.5 (4.8, 6.2) 67 11.3 (4.7, 20.9) 2.05 (0.98, 4.32)
>3 cm - ≤7 cm
Limited 3,391 21.6 (20.1, 23.1) 255 38.9 (32.3, 45.3) 1.80 (1.50, 2.16)‡
Distant 6,817 4.2 (3.7, 4.7) 210 3.7 (1.6, 7.0) 0.88 (0.41, 1.87)
>7 cm
Limited 1,071 15.6 (13.3, 18.0) 117 37.0 (27.8, 46.3) 2.37 (1.76, 3.19)‡
Distant 3,079 4.9 (4.1, 5.7) 135 12.6 (7.3, 19.5) 2.57 (1.55, 4.27)‡
Year of diagnosis
1992-2000
Limited 6,660 18.9 (17.9, 19.9) 364 40.9 (35.5, 46.3) 2.16 (1.87, 2.50)‡
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Table 3 Stage-specific three-year relative survival of patients with small cell lung carcinoma and extrapulmonary small
cell carcinoma diagnosed in SEER-13 according to gender, age, and calendar year, 1992-2010* (Continued)
Distant 14,006 3.5 (3.2, 3.8) 314 5.5 (3.2, 8.5) 1.57 (0.98, 2.53)
2001-2010
Limited 5,410 23.0 (21.7, 24.2) 543 43.8 (39.1, 48.4) 1.90 (1.69, 2.14)‡
Distant 14,997 4.4 (4.1, 4.8) 521 6.7 (4.6, 9.3) 1.52 (1.06, 2.19)‡
Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, No. number, RS relative survival, RSR RS ratio, SCLC small cell lung carcinoma,
SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results (SEER) Program.
* Based on microscopically confirmed cases of small cell carcinoma diagnosed during 1992–2010 and followed through 2011. To allow a general overview of
stage across primary sites, we used the SEER historic stage variable that includes localized (confined to the organ of origin), regional (direct extension to adjacent
organ/tissue or regional lymph nodes), distant (discontinuous metastases), and unspecified stages. We combined localized and regional stages into the category
of “limited” stage and maintained the distant stage variable as defined in the SEER Program.
†Stage was not specified for 1,760 cases of SCLC (3-year RS (%) = 12.1, 95 % CI = 10.5, 13.8), and 162 cases of EPSCC (3-year RS (%) = 21.0, 95 % CI = 14.6, 28.2).
‡ 95 % CI excludes 1.00 (based on unrounded upper and lower CI), and RSR is significant (P < 0.05).
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ethnicity), access to health care, and publication bias.
Among EPSCC, we report the highest incidence for
the urinary bladder, a site that may clinically manifest
early with hematuria or urinary symptoms, as supported
by the more than triple number of cases diagnosed with
limited stage than distant stage disease. The IRs were
next highest for prostate and uterine cervix, both sites
for which some form of cancer screening was available
during the entire study period. For EPSCC of the cervix
and female breast, there were more than twice as many
cases with limited than distant stage, as would be ex-
pected in screen-detected cancers. However, there were
62% more distant than limited stage cases for the pros-
tate, confirming findings in a prior SEER-based study
(1973–2003) [21]. In combination, these findings raise
the possibility that small cell carcinoma of the prostate
may be associated with more aggressive biology than other
sites for which screening is similarly available. However,
alternate explanations, including a delay in diagnosis due
to urinary symptoms being attributed to other causes, a
missed finding of co-existing small cell carcinoma with
adenocarcinoma of the prostate, or absence of elevation in
prostate-specific antigen [22] could also account for the
predominance of distant stage disease.
Incidence rates for SCLC and nearly all evaluable site-
specific EPSCC were higher among males than females.
This gender disparity in incidence has been similarly de-
scribed for many other cancers [23]. While we noted
a female predominance of EPSCC prior to age 55 years,
this was driven by sex-specific cancer sites (uterine cervix,
ovary). An early-onset incidence pattern has been de-
scribed for cervical [24] and ovarian cancers [25], and
whether human papillomavirus and hormonal factors, re-
spectively, are risk factors for small cell carcinoma of these
sites remains to be determined.
Lung cancer incidence rates among males and fe-
males have correlated with prior prevalence of tobacco
use, in particular for SCLC and squamous cell carcin-
oma [26-28], thereby supporting the hypothesis thatsmall cell carcinomas may share risk factors with non-
small cell carcinomas occurring at the same site. Our
study extends previous SEER-based reports [26,29], and
we describe a continued decline in incidence of SCLC
through 2010. In contrast to the significant decline in inci-
dence during 1992–2010 observed for SCLC, a smoking-
related cancer, the overall incidence of EPSCC increased.
A rise in incidence was most notable for small cell carcin-
oma of the urinary bladder, despite cigarette smoking be-
ing an established risk factor for both lung and urinary
bladder cancers. The increase in small cell carcinoma of
the urinary bladder suggests a role for risk factor(s) other
than tobacco, including occupational exposures. This find-
ing is further supported by the decrease in incidence of
papillary, squamous, and adenocarcinomas of the bladder
since the early 1990s in the U.S., in contrast to the rise in
small cell carcinoma previously described [30]. Therefore,
the opposing trends of bladder cancer by histologic sub-
type makes early detection an unlikely explanation for the
rising incidence of small cell carcinoma of the urinary
bladder, as a similar direction in trend would be expected
across histologic subtypes.
Consistent with some [8,9], but not all [31] prior re-
ports, we found that RS was significantly more favorable
for EPSCC than SCLC. In the U.S. and England, small
cell carcinoma of female breast is associated with among
the most favorable survival [8,9]. We also found survival
for limited stage small cell carcinoma of salivary gland to
be favorable, although based on few cases. Younger age
and smaller tumor size were also associated with more fa-
vorable survival among limited stage SCLC and EPSCC.
These findings are in agreement with a SEER-based
study of EPSCC (1973–2006) where age ≥50 years, tumor
size ≥5 cm, regional stage, and distant stage were identified
as predictors of survival in multivariate analysis [8]. While
several population-based studies [8,9,32] and single institu-
tion studies [31,33-41] have evaluated survival of EPSCC,
comparison between studies is difficult due to varying mea-
sures of survival calculated, in addition to the extent to
which staging and treatment information is considered;
Table 4 Stage-specific three-year relative survival of
patients with extrapulmonary small cell carcinoma
diagnosed in SEER-13 according to site, 1992-2010*
No. RS (%) (95% CI) RSR (95% CI)
Limited stage
Uterine cervix 164 51.6 (43.3, 59.2) 1.00
Salivary glands 27 67.7 (41.9, 83.9) 1.31 (0.93, 1.86)
Esophagus 56 33.2 (20.6, 46.3) 0.64 (0.42, 0.98)†
Stomach 18 ~ ~
Colon/rectum 59 40.0 (26.5, 53.2) 0.78 (0.53, 1.13)
Pancreas 15 ~ ~
Larynx 31 34.0 (17.7, 51.0) 0.66 (0.39, 1.12)
Female breast 39 62.5 (42.3, 77.3) 1.21 (0.88, 1.68)
Ovary 33 41.0 (23.9, 57.4) 0.79 (0.51, 1.24)
Prostate 50 36.4 (21.5, 51.4) 0.71 (0.45, 1.10)
Urinary bladder 256 40.5 (33.6, 47.4) 0.78 (0.62, 0.99)†
Distant stage
Uterine cervix 74 9.4 (3.8, 18.0) 1.00
Salivary glands 12 ~ ~
Esophagus 75 1.4 (0.1, 6.7) 0.15 (0.02, 1.22)
Stomach 42 5.1 (0.9, 15.2) 0.54 (0.12, 2.56)
Colon/rectum 116 2.2 (0.4, 6.6) 0.23 (0.05, 1.10)
Pancreas 118 1.8 (0.3, 5.8) 0.19 (0.04, 0.96)†
Larynx 2 ~ ~
Female breast 14 ~ ~
Ovary 65 19.9 (10.8, 31.0) 2.12 (0.83, 5.37)
Prostate 88 7.4 (2.9, 14.9) 0.79 (0.26, 2.43)
Urinary bladder 87 2.9 (0.6, 9.0) 0.31 (0.07, 1.46)
Abbreviations: CI confidence interval, No. number, RS relative survival, RSR RS
ratio, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and
End Results Program, ~ relative survival not calculated for < 25 cases.
*Based on microscopically confirmed cases of small cell carcinoma diagnosed
during 1992–2010 and followed through 2011. To allow a general overview
of stage across primary sites, we used the SEER historic stage variable that
includes localized (confined to the organ of origin), regional (direct extension
to adjacent organ/tissue or regional lymph nodes), distant (discontinuous
metastases), and unspecified stages. We combined localized and regional
stages into the category of “limited” stage and maintained the distant stage
variable as defined in the SEER Program.
†95 % CI excludes 1.00 (based on unrounded upper and lower CI), and RSR is
significant (P < 0.05).
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tics (e.g., race/ethnicity, socioeconomic status) are reflected
in study populations. Additionally, with site-specific vari-
ation in survival of EPSCC, the entities included within the
category of EPSCC across studies are likely to influence
overall survival estimates.
A modest improvement in survival of SCLC has been re-
ported since the 1970s and 1980s [42,43], and we observed
a slight, but statistically significant, improvement in limited
and extensive stage SCLC RS and a nonsignificant improve-
ment in EPSCC RS subsequent to the 1990s. Despite statis-
tical associations, clinically, the minimal change in survivalover time likely reflects the lack of new therapies available
for SCLC, with platinum agents remaining the mainstay of
therapy since the 1980s [43]. Although the optimal treat-
ment for EPSCC is unknown, it is often managed like SCLC
[31], and while identification of new agents in the future
may affect survival of both SCLC and EPSCC, variable re-
sponse by site of disease might be expected based on histor-
ically reported differences in site-specific survival.
The strength of our population-based study includes
the large size which allowed evaluation of incidence and
patient survival by site. Despite its large size, we did not
have sufficient cases of EPSCC to assess age-specific IRs,
temporal trends, or RS for every specified site. Pathology
was not centrally reviewed, so we cannot exclude the pos-
sibility of misclassification of other histologic entities char-
acterized by small cells [14], including well differentiated
neuroendocrine tumors. Our survival analyses did not in-
clude information on prognostic indicators such as per-
formance status, lactate dehydrogenase, or weight loss
because this information is not collected by the SEER
Program. Additionally, we did not consider treatment or
response to treatment in our survival analyses because
treatment data (surgery, radiation) are limited to the first
course of therapy, and information on chemotherapy, the
mainstay of treatment for small cell carcinoma, is not
publicly available. Lastly, our staging dichotomy (limited
vs. distant stage) may have resulted in misclassification by
stage, thereby yielding conservative RS estimates for lim-
ited stage disease and optimistic RS estimates for distant
stage disease.
Conclusions
In summary, distinct incidence patterns suggest that there
are etiologic differences between SCLC and EPSCC. Op-
posing temporal trends for SCLC and EPSCC since the
1990s support a less important role for cigarette smoking
in EPSCC overall than in SCLC. Gender disparities in inci-
dence of site-specific EPSCC further implicate distinct ex-
posures and/or inherent susceptibility differences by site.
Disease biology of EPSCC also appears to differ by primary
site, as demonstrated by some screen-detectable cancer
sites presenting predominantly with limited stage disease
(e.g., uterine cervix, female breast) in contrast to other sites
where distant stage disease predominated (e.g., prostate).
Lastly, while a survival advantage was evident for limited
stage EPSCC compared to SCLC, the advantage was less
pronounced for distant stage small cell carcinoma which
was associated with dismal survival across nearly all sites.
The generally poor survival associated with small cell car-
cinoma underscores the importance of understanding dis-
ease etiology, identifying prevention/screening modalities,
considering new treatment approaches, and ensuring that
older patients and racially/ethnically diverse populations
are included in clinical trials of new agents.
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